In vivo real-time tracking of “color-coded” supercharged Mesenchymal Stem Cells and T cells in allograft rejection

在存在独特的免疫信号传导蛋白（IL-17）的情况下生长特化的成体干细胞（MSC）已经产生了具有上级能力的“增压”干细胞，以抑制细胞和器官移植患者的免疫应答。在移植患者中使用这些MSC可以显着减少预防细胞和器官排斥所需的抗排斥药物的剂量。通过最大限度地减少药物剂量，我们的目标是消除这些患者发生感染和癌症的风险。

Growing specialized adult stem cells (MSC) in the presence of a unique immune signaling protein (IL-17) has generated a “supercharged” stem cell with superior abilities to dampen immune responses in cell and organ transplant patients. The use of these MSC in transplant patients may significantly reduce the dose of anti-rejection drugs required to prevent cell and organ rejection. By minimizing the dose of drugs, we aim to eliminate the risk of developing infections and cancer in these patients.